Eris Lifesciences Ltd
Eris Lifesciences Ltd (ERIS) last traded at ₹1,315, a market capitalisation of ₹18,223 crore, on a P/E of 27.8. Over the past 52 weeks the stock has ranged between ₹1,200 and ₹1,819. Eris Lifesciences Ltd last reported results for the quarter ended Jun 2026, with sales of ₹873 crore and net profit of ₹143 crore. The next scheduled event is an analyst meet on 27 Aug 2026. Figures are as of 25 Aug 2026 and are not real time.
Eris Lifesciences Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Eris Lifesciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹873 cr, up 12.9% from ₹773 cr a year earlier. Net profit was ₹143 cr, up 14.4% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 741 | 727 | 705 | 773 | 792 | 807 | 757 | 873 |
| Expenses | 477 | 477 | 453 | 496 | 504 | 526 | 484 | 577 |
| Operating profit | 265 | 250 | 252 | 277 | 288 | 282 | 272 | 296 |
| OPM % | 36% | 34% | 36% | 36% | 36% | 35% | 36% | 34% |
| Other income | 5 | 4 | 8 | 4 | 3 | -17 | 2 | 2 |
| Interest | 59 | 57 | 54 | 49 | 50 | 49 | 46 | 47 |
| Depreciation | 80 | 81 | 77 | 71 | 69 | 70 | 70 | 72 |
| Profit before tax | 129 | 116 | 129 | 161 | 173 | 145 | 159 | 179 |
| Tax % | 25% | 25% | 21% | 22% | 22% | 25% | -75% | 20% |
| Net profit | 96 | 87 | 102 | 125 | 134 | 109 | 279 | 143 |
| EPS (₹) | 6.73 | 6.15 | 6.89 | 8.66 | 8.82 | 7.32 | 20.33 | 10.28 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Eris Lifesciences Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 1,212 | 1,347 | 1,685 | 2,009 | 2,894 | 3,129 | 3,230 |
| Operating profit | 431 | 489 | 539 | 677 | 1,018 | 1,120 | 1,138 |
| OPM % | 36% | 36% | 32% | 34% | 35% | 36% | 35% |
| Net profit | 355 | 406 | 374 | 397 | 375 | 648 | 666 |
| EPS (₹) | 26.16 | 29.88 | 28.10 | 28.82 | 25.84 | 44.72 | 46.75 |
TTM is the trailing twelve months to the most recent quarter.
Eris Lifesciences Ltd growth and returns
- 10 Years
- 18%
- 5 Years
- 21%
- 3 Years
- 23%
- TTM
- 10%
- 10 Years
- 17%
- 5 Years
- 12%
- 3 Years
- 19%
- TTM
- 69%
- 10 Years
- %
- 5 Years
- 13%
- 3 Years
- 17%
- 1 Year
- -26%
- 10 Years
- 21%
- 5 Years
- 18%
- 3 Years
- 16%
- Last Year
- 19%
Eris Lifesciences Ltd shareholding pattern
Promoters held 54.14% at Jun 2026, down from 54.83% at Jun 2025. FIIs 5.76% and DIIs 20.71%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 54.87% | 54.86% | 54.85% | 54.83% | 54.85% | 54.85% | 53.92% | 54.14% |
| FIIs | 8.01% | 8.36% | 8.43% | 8.39% | 7.21% | 6.85% | 6.39% | 5.76% |
| DIIs | 18.64% | 18.07% | 18.07% | 18.18% | 19.36% | 20.31% | 20.35% | 20.71% |
| Public | 18.47% | 18.73% | 18.64% | 18.59% | 18.57% | 17.97% | 19.33% | 19.39% |
| No. of shareholders | 46,346 | 53,314 | 50,087 | 52,225 | 59,438 | 54,713 | 51,656 | 50,798 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Eris Lifesciences Ltd events
The next scheduled event is an analyst meet on 27 Aug 2026.
- Analyst meet1x1 meeting with HBM Partners AG
See the full results calendar for every Indian company reporting in the next 30 days.
Eris Lifesciences Ltd corporate filings
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationCompany Updatelow impact
Cruxal's analysis: Eris Lifesciences has issued an intimation regarding an upcoming analyst/investor…
Read the full analysis - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationCompany Updatelow impact
Cruxal's analysis: Eris Lifesciences has issued an intimation regarding an upcoming analyst and investor…
Read the full analysis - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationCompany Updatelow impact
Cruxal's analysis: Eris Lifesciences has issued an intimation regarding an upcoming analyst/investor…
Read the full analysis - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015, - Availing Working Capital Term Loan From Axis BankCompany Updatelow impact
Cruxal's analysis: Eris Lifesciences has disclosed the availing of a working capital term loan facility from…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Eris Lifesciences Ltd
Cruxal reads every Eris Lifesciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.